174 related articles for article (PubMed ID: 23238015)
1. JAK2/STAT5 inhibition circumvents resistance to PI3K/mTOR blockade: a rationale for cotargeting these pathways in metastatic breast cancer.
Britschgi A; Andraos R; Brinkhaus H; Klebba I; Romanet V; Müller U; Murakami M; Radimerski T; Bentires-Alj M
Cancer Cell; 2012 Dec; 22(6):796-811. PubMed ID: 23238015
[TBL] [Abstract][Full Text] [Related]
2. PI3K inhibition circumvents resistance to SHP2 blockade in metastatic triple-negative breast cancer.
Amante RJ; Jehanno C; De Silva D; Coissieux MM; Ackerknecht M; Romanet V; Sethi A; Hamelin B; Preca BT; Piscuoglio S; Ng CKY; Mohseni M; Bentires-Alj M
J Mammary Gland Biol Neoplasia; 2023 Jun; 28(1):13. PubMed ID: 37294349
[TBL] [Abstract][Full Text] [Related]
3. Targeting PI3K, HER2 and the IL-8/JAK2 axis in metastatic breast cancer: Which combination makes the whole greater than the sum of its parts?
Britschgi A; Radimerski T; Bentires-Alj M
Drug Resist Updat; 2013; 16(3-5):68-72. PubMed ID: 24169539
[TBL] [Abstract][Full Text] [Related]
4. Tyrosine phosphatase SHP2 increases cell motility in triple-negative breast cancer through the activation of SRC-family kinases.
Sausgruber N; Coissieux MM; Britschgi A; Wyckoff J; Aceto N; Leroy C; Stadler MB; Voshol H; Bonenfant D; Bentires-Alj M
Oncogene; 2015 Apr; 34(17):2272-8. PubMed ID: 24931162
[TBL] [Abstract][Full Text] [Related]
5. JAK2-STAT5 signaling: A novel mechanism of resistance to targeted PI3K/mTOR inhibition.
Yeh JE; Toniolo PA; Frank DA
JAKSTAT; 2013 Oct; 2(4):e24635. PubMed ID: 24470973
[TBL] [Abstract][Full Text] [Related]
6. Exit from pluripotency is gated by intracellular redistribution of the bHLH transcription factor Tfe3.
Betschinger J; Nichols J; Dietmann S; Corrin PD; Paddison PJ; Smith A
Cell; 2013 Apr; 153(2):335-47. PubMed ID: 23582324
[TBL] [Abstract][Full Text] [Related]
7. Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis.
Bonapace L; Coissieux MM; Wyckoff J; Mertz KD; Varga Z; Junt T; Bentires-Alj M
Nature; 2014 Nov; 515(7525):130-3. PubMed ID: 25337873
[TBL] [Abstract][Full Text] [Related]
8. PIK3CA(H1047R) induces multipotency and multi-lineage mammary tumours.
Koren S; Reavie L; Couto JP; De Silva D; Stadler MB; Roloff T; Britschgi A; Eichlisberger T; Kohler H; Aina O; Cardiff RD; Bentires-Alj M
Nature; 2015 Sep; 525(7567):114-8. PubMed ID: 26266975
[TBL] [Abstract][Full Text] [Related]
9. Activation of MAPK pathways due to DUSP4 loss promotes cancer stem cell-like phenotypes in basal-like breast cancer.
Balko JM; Schwarz LJ; Bhola NE; Kurupi R; Owens P; Miller TW; Gómez H; Cook RS; Arteaga CL
Cancer Res; 2013 Oct; 73(20):6346-58. PubMed ID: 23966295
[TBL] [Abstract][Full Text] [Related]
10. Tumor STAT3 tyrosine phosphorylation status, as a predictor of benefit from adjuvant chemotherapy for breast cancer.
Sonnenblick A; Uziely B; Nechushtan H; Kadouri L; Galun E; Axelrod JH; Katz D; Daum H; Hamburger T; Maly B; Allweis TM; Peretz T
Breast Cancer Res Treat; 2013 Apr; 138(2):407-13. PubMed ID: 23446809
[TBL] [Abstract][Full Text] [Related]
11. Hypoxia/HIF1α induces lapatinib resistance in ERBB2-positive breast cancer cells via regulation of DUSP2.
Karakashev SV; Reginato MJ
Oncotarget; 2015 Feb; 6(4):1967-80. PubMed ID: 25596742
[TBL] [Abstract][Full Text] [Related]
12. Mitochondrial dysfunction in some triple-negative breast cancer cell lines: role of mTOR pathway and therapeutic potential.
Pelicano H; Zhang W; Liu J; Hammoudi N; Dai J; Xu RH; Pusztai L; Huang P
Breast Cancer Res; 2014 Sep; 16(5):434. PubMed ID: 25209360
[TBL] [Abstract][Full Text] [Related]
13. Mesenchymal precursor cells maintain the differentiation and proliferation potentials of breast epithelial cells.
Duss S; Brinkhaus H; Britschgi A; Cabuy E; Frey DM; Schaefer DJ; Bentires-Alj M
Breast Cancer Res; 2014 Jun; 16(3):R60. PubMed ID: 24916766
[TBL] [Abstract][Full Text] [Related]
14. How pregnancy at early age protects against breast cancer.
Meier-Abt F; Bentires-Alj M
Trends Mol Med; 2014 Mar; 20(3):143-53. PubMed ID: 24355762
[TBL] [Abstract][Full Text] [Related]
15. The Hippo kinases LATS1 and 2 control human breast cell fate via crosstalk with ERα.
Britschgi A; Duss S; Kim S; Couto JP; Brinkhaus H; Koren S; De Silva D; Mertz KD; Kaup D; Varga Z; Voshol H; Vissieres A; Leroy C; Roloff T; Stadler MB; Scheel CH; Miraglia LJ; Orth AP; Bonamy GM; Reddy VA; Bentires-Alj M
Nature; 2017 Jan; 541(7638):541-545. PubMed ID: 28068668
[TBL] [Abstract][Full Text] [Related]
16. CRISPR screen identifies genes that sensitize AML cells to double-negative T-cell therapy.
Soares F; Chen B; Lee JB; Ahmed M; Ly D; Tin E; Kang H; Zeng Y; Akhtar N; Minden MD; He HH; Zhang L
Blood; 2021 Apr; 137(16):2171-2181. PubMed ID: 33270841
[TBL] [Abstract][Full Text] [Related]
17. Boolean modeling of breast cancer signaling pathways uncovers mechanisms of drug synergy.
Taoma K; Ruengjitchatchawalya M; Liangruksa M; Laomettachit T
PLoS One; 2024; 19(2):e0298788. PubMed ID: 38394152
[TBL] [Abstract][Full Text] [Related]
18. Identification and validation of the association of Janus kinase 2 mutations with the response to immune checkpoint inhibitor therapy.
Chen P; Long J; Zhang J; Xie F; Wu W; Tian Z; Zhang S; Yu K
Inflamm Res; 2024 Feb; 73(2):263-276. PubMed ID: 38200372
[TBL] [Abstract][Full Text] [Related]
19. Bromodomain and extraterminal (BET) proteins: biological functions, diseases, and targeted therapy.
Wang ZQ; Zhang ZC; Wu YY; Pi YN; Lou SH; Liu TB; Lou G; Yang C
Signal Transduct Target Ther; 2023 Nov; 8(1):420. PubMed ID: 37926722
[TBL] [Abstract][Full Text] [Related]
20. Double-edged sword of JAK/STAT signaling pathway in viral infections: novel insights into virotherapy.
Mahjoor M; Mahmoudvand G; Farokhi S; Shadab A; Kashfi M; Afkhami H
Cell Commun Signal; 2023 Oct; 21(1):272. PubMed ID: 37784164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
